原发性肝癌术后行肝动脉化疗栓塞治疗对患者生存及肿瘤复发的影响

目的：探讨原发性肝癌术后行肝动脉化疗栓塞（TACE）对患者生存及肿瘤复发的影响。方法：对原发性肝癌行肝部分切除、临床病例资料完整的患者行回顾性分析,分为术后行TACE组（实验组,103例）及未行TACE组（对照组,118例）,分别计算2组患者1年、2年及3年的生存率及肿瘤复发率。结果：2组患者在性别、年龄、HBV感染、分化程度、肿瘤大小、有无血管癌栓及肿瘤TNM分期方面差异均无统计学意义（P〉0.05）,实验组1年、2年及3年的生存率分别为95.1%、65.0%、40.8%,对照组为71.2%、40.7%,21.2%,差异有统计学意义（P〈0.01）,实验组肿瘤1年复发率为22.3%,对照组为40.7%,差异有统计学意义（P〈0.01）,实验组2年、3年的复发率为57.3%、73.8%,对照组为61.9%、78%,差异无统计学意义（P〉0.05）。结论：肝癌术后行TACE可提高患者远期生存率,降低肿瘤的近期复发率。

Effects on the patients survival and tumour recurrence of transcatheter arterial chemoembolization treatment after hepatectomy for primary hepatocellular carcinoma

Objective： To explore the effects on the patients＇ survival and tumour recurrence of transcatheter arterial chemoembolization（TACE） treatment after hepatectomy for primary hepatocellular carcinoma.Methods： Retrospectively analyzed clinical data of patients who received partial liver resection due to primary liver carcinoma.Patients were divided into two groups： experimental group（103 cases） with TACE treatment after hepatectomy and control group（118 cases） without TACE treatment.Survival rate and tumour recurrence rate of these two groups in the first year,the second year and the third year were calculated respectively.Results： There was no significant difference in the discrepancy of gender,age,HBV infection,differentiation,tumour diameter,with vascular thrombosis or not and TNM stage of tumour between the two groups（P〉0.05）.Survival rate of experimental group was 95.1%,65.0% and 40.8% in the first,second and third year respectively,while 71.2%,40.7%,21.2% for control group,with apparent difference（P〈0.01） between the two groups.The tumour recurrence rate in the first year was 22.3% for experimental group,40.7% for the control group,which indicated significant difference（P〈0.01）.However the tumour recurrence in the second and third year was 57.3%,73.8% for the experimental group and 61.9%,78% for the control group,which suggestd no significant difference（P〉0.05）.Conclusions： TACE treatment after hepatectomy for primary hepatocellular carcinoma can significantly increase the patients＇ survival rate and decrease short-term tumour recurrence rate.